Axxcess Wealth Management LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 38.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 92,133 shares of the company's stock after acquiring an additional 25,652 shares during the quarter. Axxcess Wealth Management LLC's holdings in Johnson & Johnson were worth $14,425,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the business. California Public Employees Retirement System lifted its holdings in Johnson & Johnson by 4.9% during the fourth quarter. California Public Employees Retirement System now owns 10,620,264 shares of the company's stock valued at $1,664,620,000 after purchasing an additional 498,647 shares during the last quarter. Raymond James & Associates lifted its position in shares of Johnson & Johnson by 0.4% during the fourth quarter. Raymond James & Associates now owns 6,061,707 shares of the company's stock worth $950,112,000 after acquiring an additional 26,982 shares in the last quarter. Ninety One UK Ltd boosted its holdings in shares of Johnson & Johnson by 0.3% in the fourth quarter. Ninety One UK Ltd now owns 4,436,013 shares of the company's stock worth $695,301,000 after acquiring an additional 12,867 shares during the period. DekaBank Deutsche Girozentrale raised its stake in shares of Johnson & Johnson by 4.8% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 4,396,416 shares of the company's stock valued at $688,198,000 after purchasing an additional 200,193 shares during the period. Finally, Stifel Financial Corp boosted its stake in Johnson & Johnson by 2.9% in the 3rd quarter. Stifel Financial Corp now owns 4,306,268 shares of the company's stock worth $670,726,000 after purchasing an additional 120,891 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.
Johnson & Johnson Stock Up 0.2 %
Shares of NYSE:JNJ traded up $0.23 during trading on Wednesday, hitting $148.95. The stock had a trading volume of 7,089,073 shares, compared to its average volume of 7,436,958. The company has a market capitalization of $358.47 billion, a PE ratio of 9.29, a PEG ratio of 2.46 and a beta of 0.55. The firm's fifty day moving average is $153.70 and its 200 day moving average is $154.97. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the prior year, the firm earned $2.68 EPS. The company's revenue was up 2.3% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a $1.24 dividend. The ex-dividend date is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.33%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.19. Johnson & Johnson's dividend payout ratio is presently 30.92%.
Insider Buying and Selling at Johnson & Johnson
In other news, EVP Jennifer L. Taubert sold 59,397 shares of the firm's stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company's stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company's stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the stock. HSBC upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating and raised their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Bank of America lowered their price objective on Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 17th. Morgan Stanley reduced their target price on Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday. Finally, Royal Bank of Canada decreased their price objective on shares of Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $175.86.
Get Our Latest Research Report on JNJ
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
